Search results for "ALAT"

showing 10 items of 4241 documents

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Providing choice and/or variety during a meal: Impact on vegetable liking and intake

2016

Food choice is defined as providing the opportunity for an individual to select the food he or she wants to consume while food variety is defined as providing an individual with foods that differ on at least one sensory characteristic. Literature shows that providing food choice or providing food variety may increase meal enjoyment and food intake. However, these two factors have been mainly investigated separately, while they may actually co-occur in real-life settings. In fact, in many out-of-home catering situations, individuals have the possibility to choose as many dishes as they desire from among different proposals for their meal. The aim of the present study was to assess the impact…

0301 basic medicineMaleFood intakerepas[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionFood choiceFood likingmealFood varietyChoice BehaviorBody Mass IndexToxicologyEatingFood intakeSurveys and QuestionnairesFood choiceVegetablesPlate clearersIntrinsic motivationchildrens likingPalatabilityMealsintrinsic motivationGeneral Psychologychoice2. Zero hungerMealNutrition and Dieteticsdigestive oral and skin physiologyfood-intakevarietyrandomized controlled-trialFemalePsychologyeffective strategyAdultpleasureplaisirnormal-weight03 medical and health sciencesFood PreferencesYoung AdultacceptabilityLunch timeHumansEating behaviorconsumption030109 nutrition & dieteticsfoodBody WeightplateVariety (linguistics)Diet[SDV.AEN] Life Sciences [q-bio]/Food and Nutritionpalatability[SDV.AEN]Life Sciences [q-bio]/Food and NutritionOlive oil
researchProduct

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/…

2017

Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design: Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different defin…

0301 basic medicineMaleHIV InfectionsAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Microbiology (medical); Infectious DiseasesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; RNA Viral; Raltegravir Potassium; Ritonavir; Viral LoadGastroenterologyCohort StudiesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability0302 clinical medicineMedicineNRTI-sparing regimen030212 general & internal medicineViralDarunavireducation.field_of_studyLamivudineGeneral MedicineMiddle AgedViral LoadTolerabilityAntiretroviral therapyInfectious DiseasesTolerabilityItalyCombinationRNA ViralDrug Therapy CombinationFemaleViral loadmedicine.drugAdultMicrobiology (medical)medicine.medical_specialtyEfficacyAnti-HIV Agents030106 microbiologyPopulationDarunavir/ritonavir; Raltegravir; Efficacy; Tolerability; Antiretroviral therapy; NRTI-sparing regimenSettore MED/17 - MALATTIE INFETTIVELower riskNO03 medical and health sciencesDrug TherapyInternal medicineRaltegravir PotassiumHumanseducationDarunavirRitonavirbusiness.industryDarunavir/ritonavirRaltegravirRaltegravirHIV-1RNARitonavirbusinessAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability;
researchProduct

Exposure to Bisphenol A and Phthalates during Pregnancy and Ultrasound Measures of Fetal Growth in the INMA-Sabadell Cohort

2016

Background: Prenatal exposure to bisphenol A (BPA) and phthalates may affect fetal growth; however, previous findings are inconsistent and based on few studies. Objectives: We assessed whether prenatal exposure to BPA and phthalates was associated with fetal growth in a Spanish birth cohort of 488 mother–child pairs. Methods: We measured BPA and eight phthalates [four di(2-ethylhexyl) phthalate metabolites (DEHPm), mono-benzyl phthalate (MBzP), and three low-molecular-weight phthalate metabolites (LMWPm)] in two spot-urine samples collected during the first and third trimester of pregnancy. We estimated growth curves for femur length (FL), head circumference (HC), abdominal circumference (A…

0301 basic medicineMaleHealth Toxicology and MutagenesisEmbaràsFetal growth010501 environmental sciences01 natural sciencesCohort StudiesFetal DevelopmentBisphenol APhthalatesPregnancyPrenatal exposureFetal growthBirth WeightMaternal-Fetal ExchangeMaternal-fetal exchangePhenols toxicityObstetricsÀcid ftàlicEnvironmental exposureMaternal ExposureCohortChildren's HealthINMA study/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingChristian ministryFemaleUltrasonographyAdultmedicine.medical_specialtyAdolescentPhthalic AcidsUltrasonography Prenatal03 medical and health sciencesBisfenol A -- Toxicologia -- EpidemiologiaPhenolsSDG 3 - Good Health and Well-beingmedicineHumansBenzhydryl Compounds0105 earth and related environmental sciencesPregnancybusiness.industryPublic Health Environmental and Occupational HealthInfant NewbornSabadell (Barcelona Spain)Environmental Exposuremedicine.disease030104 developmental biologySpainbusiness
researchProduct

The burden and epidemiology of community-acquired central nervous system infections: a multinational study

2017

Ghaydaa, Shehata/0000-0002-3631-893X; Radic, Ljiljana Betica/0000-0002-8778-106X; Silva-Pinto, Andre/0000-0002-2077-3356; Cascio, Antonio/0000-0002-1992-1796; Bossi, Paolo/0000-0003-0135-0224; Stebel, Roman/0000-0001-6922-4465; Namani, Sadie/0000-0002-2411-8623; Chan, Phillip/0000-0002-4071-4409; Hargreaves, Sally/0000-0003-2974-4348; Artuk, Cumhur/0000-0003-0827-990X; Harxhi, Arjan/0000-0001-8518-7377; Larsen, Lykke/0000-0002-4113-4182; Uysal, Serhat/0000-0002-4294-5999 WOS: 000407582200010 PubMed: 28397100 Risk assessment of central nervous system (CNS) infection patients is of key importance in predicting likely pathogens. However, data are lacking on the epidemiology globally. We perfor…

0301 basic medicineMaleOutcome AssessmentAdverse Clinical Outcomemedicine.disease_causeCentral nervous system infections ; burden ; epidemiologyMedical microbiologyCentral Nervous System InfectionsOutcome Assessment Health CareEpidemiology80 and overAged 80 and overbiologyAge FactorsGeneral MedicineMiddle AgedCommunity-Acquired InfectionsInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyPopulation SurveillanceFemaleNeuroborreliosisHuman Immunodeficiency VirusMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisSettore MED/17 - Malattie Infettive030106 microbiologyBrain AbscessCentral Nervous System InfectionNeurosyphilisMycobacterium tuberculosis03 medical and health sciencesYoung AdultInternal medicineStreptococcus pneumoniaeJournal ArticlemedicineHumansAgedRetrospective Studiesbusiness.industryVaricella zoster virusmedicine.diseasebiology.organism_classificationHealth CareCross-Sectional StudiesCentral Nervous System DiseaseBrain AbsceHuman Immunodeficiency ViruImmunologybusiness
researchProduct

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

2018

Abstract Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromis…

0301 basic medicineMalePediatricsEtiologyMultidrug-resistant pathogenMRSAPneumocystis pneumoniaPneumònia adquirida a la comunitatHOSPITALIZED-PATIENTS0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsPrevalenceMedicine030212 general & internal medicinePNEUMOCYSTIS PNEUMONIAArticles and CommentariesAged 80 and overRespiratory tract infectionsAnemia AplasticMiddle Aged3. Good healthCommunity-Acquired InfectionsEuropeInfectious DiseasesImmunocompromise; Microbiology; MRSA; Multidrug-resistant pathogens; PneumoniaEtiologiaHematologic NeoplasmsFemaleBLOOD-STREAM INFECTIONSLung TransplantationMicrobiology (medical)medicine.medical_specialtyAsiaNeutropeniaCommunity-acquired pneumonia030106 microbiologyRESPIRATORY-TRACT INFECTIONSHematologic NeoplasmsSettore MED/10 - Malattie Dell'Apparato RespiratorioTRANSPLANT RECIPIENTSDISEASES-SOCIETYMicrobiology03 medical and health sciencesImmunocompromised HostPneumonia BacterialMANAGEMENTHumanspneumoniaBACTERIAL PNEUMONIAImmunocompromiseAgedAcquired Immunodeficiency Syndromebusiness.industrymicrobiologyBacterial pneumoniaAustraliaPneumoniamedicine.diseaseMultidrug-resistant pathogensPneumoniamultidrug-resistant pathogensMycosesBacteremiaAfricaEtiologyRISK-FACTORSimmunocompromiseAmericasbusinessClinical Infectious Diseases
researchProduct

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

2019

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility…

0301 basic medicineMaleStreptococcus pneumoniaantibiotic resistanceInternationalitysputum examinationbronchiectasisvery elderlyAntibioticsPrevalenceDrug resistancemedicine.disease_causeLogistic regressionGlobal HealthCommunity-Acquired Infections/epidemiologylung lavage0302 clinical medicineCommunity-acquired pneumoniaCost of IllnessRisk FactorsPrevalencedrug resistant Streptococcus pneumoniae pneumonia030212 general & internal medicineMicrobial drug resistantAged 80 and overadultinternational cooperationdrug effectMiddle Agedinfluenza vaccinationAnti-Bacterial Agentsantiinfective agentEuropeCommunity-Acquired InfectionsHospitalizationGlobal burden of diseaseStreptococcus pneumoniaeInfectious Diseasesrisk factorbacterium identificationFemalecommunity acquired infectioninfluenzaliver diseasepneumococcal vaccinationPneumococcal infectionhospitalizationmedicine.drugMicrobiology (medical)medicine.medical_specialtyAsiamedicine.drug_class030106 microbiologySettore MED/10 - Malattie Dell'Apparato RespiratorioArticleAnti-Bacterial Agents/pharmacology03 medical and health sciencesInternal medicineStreptococcus pneumoniaeDrug Resistance BacterialPneumonia Pneumococcal/epidemiologymedicineHumanscontrolled studyhumantetracyclineHospitalization/statistics & numerical dataAgedlevofloxacinnonhumanbusiness.industrydisease associationmicrobiologycommunity acquired pneumoniamacrolidePneumoniaasthmaSouth AmericaPneumonia Pneumococcalvaccinationmedicine.diseasemajor clinical studyantibiotic sensitivitypenicillin derivativePenicillinStreptococcus pneumoniae/drug effectsPneumoniablood examinationAfricaNorth Americamicrobiological examinationbusinessGlobal burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia
researchProduct

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

2018

Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log 10 HIV-1 RNA copies/mL (IQR …

0301 basic medicineMaleantiretroviral therapy; HIV; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Odds Ratio; Prevalence; Viral Proteins; Drug Resistance Viralantiretroviral therapy; HIV; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance; Health Policy; Infectious Diseases; Pharmacology (medical)Drug ResistanceHIV InfectionsDrug resistanceGastroenterologyInterquartile rangeOdds RatioPrevalenceHIV InfectionPharmacology (medical)ViralbiologyHealth PolicyMiddle AgedIntegraseInfectious DiseasesItalyFemaleViral loadHumanresistance epidemiologyAdultmedicine.medical_specialtytransmitted HIV drug resistanceAnti-HIV AgentsHIV; antiretroviral therapy; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance030106 microbiologyantiretroviral therapySettore MED/17 - MALATTIE INFETTIVEVirus03 medical and health sciencesrecent HIV infectionViral ProteinsInternal medicineDrug Resistance ViralmedicineViral ProteinHumansbusiness.industryAnti-HIV AgentHIVOdds ratioReverse transcriptaseConfidence intervalCD4 Lymphocyte CountMutationbiology.proteinHIV-1business
researchProduct

Total colonic aganglionosis and cleft palate in a newborn with Janus-cysteine 618 mutation of RET proto-oncogene: a case report.

2020

Abstract Background Hirschsprung disease, the most important congenital colonic dysmotility in children results from neural crest migration, differentiation, proliferation, or apoptosis defects where the rearranged during transfection (RET)-Protooncogene pathway has a central role. Although palatal and retinal anomalies in the context of chromosomopathies and some mono−/oligogenic syndromes are reported associated with Hirschsprung disease the role of inactivating RET mutations in these cases is not clarified. Case presentation We report on a dysmorphic newborn with cleft palate and palatal synechia, who showed intestinal obstruction after 24 h of life. Transient ileostomy and surgical biop…

0301 basic medicineMalecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyCongenital digestive system abnormalitieNeurocristopathyCase ReportContext (language use)RET proto-oncogenemedicine.disease_causeProto-Oncogene MasCongenital digestive system abnormalities03 medical and health sciences0302 clinical medicineGermline mutationCase-reportmedicineCarcinomaHumansCysteineHirschsprung DiseaseTotal colonic aganglionosisLoss functionGerm-Line MutationJanus KinasesNeurocristopathyMutationbusiness.industryProto-Oncogene Proteins c-retlcsh:RJ1-570Infant Newbornlcsh:Pediatricsmedicine.diseaseCleft Palate030104 developmental biologyItaly030220 oncology & carcinogenesisREarranged during TransfectionbusinessItalian journal of pediatrics
researchProduct

The metabolism of mono-(2-ethylhexyl) phthalate (MEHP) and liver peroxisome proliferation in the hamster.

1988

This study has investigated the in vivo metabolism of mono-(2-ethylhexyl) phthalate (MEHP), the initial metabolite of di-(2-ethylhexyl) phthalate in mammals, and the hepatic peroxisome proliferation induced by this compound following multiple oral administration to hamsters. Hamsters received [14C]-MEHP, by gavage, at doses of 50 and 500 mg/kg body wt on each of three consecutive days. Urine was collected every 24 hours and metabolite profiles were determined using capillary gas-chromatography. Multiple high doses of MEHP (500 mg/kg) induced a change in the relative proportions of metabolites produced. As previously reported for the rat, metabolites derived from sequential ω-following by β…

0301 basic medicineMalemedicine.medical_specialtyHealth Toxicology and MutagenesisMetabolitePhthalic AcidsHamsterPeroxisome Proliferation010501 environmental sciencesToxicology01 natural sciencesMicrobodies03 medical and health scienceschemistry.chemical_compoundOral administrationInternal medicineCricetinaeDiethylhexyl PhthalatemedicineAnimals0105 earth and related environmental sciences030102 biochemistry & molecular biologyPublic Health Environmental and Occupational HealthPhthalateMetabolismPeroxisomeRatsEndocrinologychemistryLiverGlucuronideOxidation-ReductionToxicology and industrial health
researchProduct